Wenjie Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wenjie Cai has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Peng Ji
Northwestern University, Chicago, Illinois, UNITED STATES
4 shared publications - Huiping Liu
Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL
3 shared publications - Sergio Barajas
Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL
3 shared publications - Shiyu Xiao
Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL
3 shared publications - Yan Liu
Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL
3 shared publications - Danny T. Huang
Cancer Research UK Scotland Institute, Garscube Estate, Switchback Road, Glasgow, G61 1BD, UK
2 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (17) , 5092-5120
cPRC1.2 and CTCF-mediated transition from poised to active chromatin loops at bivalent genes
Polycomb Repressive Complex 1 (PRC1) and CCCTC-binding factor (CTCF) are critical regulators of 3D chromatin architecture that influence cellular transcriptional programs. Although the role of CTCF in chromatin organization is well-known, the involvement of PRC1 is less understood. In this study, we identify an unexpected role for the canonical Pcgf2-containing PRC1 complex (cPRC1.2) in activating bivalent genes. Hi-C revealed that cPRC1.2 forms chromatin loops at bivalent promoters, rendering them poised for activation. Pcgf2 deletion disrupts cPRC1.2 loops and impairs the transcriptional induction of crucial target genes necessary for neuronal differentiation. Furthermore, we identify CTCF enrichment at cPRC1.2 loop anchors and at Polycomb group (PcG) bodies, suggesting that PRC1 and CTCF cooperatively regulate chromatin loops. Through virtual 4C and other genomic analyses, we discover that establishing neuronal progenitor cell (NPC) identity involves a switch from cPRC1.2-mediated chromatin loops to CTCF-mediated active loops. Our results suggest a novel mechanism by which pre-formed PRC1 loops at lineage-specific genes maintain a poised state for subsequent CTCF-mediated active loops and gene activation in cell fate transitions.
- 23 July 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (17) , 5092-5120
Open AccesscPRC1.2 and CTCF-mediated transition from poised to active chromatin loops at bivalent genes
Polycomb Repressive Complex 1 (PRC1) and CCCTC-binding factor (CTCF) are critical regulators of 3D chromatin architecture that influence cellular transcriptional programs. Although the role of CTCF in chromatin organization is well-known, the involvement of PRC1 is less understood. In this study, we identify an unexpected role for the canonical Pcgf2-containing PRC1 complex (cPRC1.2) in activating bivalent genes. Hi-C revealed that cPRC1.2 forms chromatin loops at bivalent promoters, rendering them poised for activation. Pcgf2 deletion disrupts cPRC1.2 loops and impairs the transcriptional induction of crucial target genes necessary for neuronal differentiation. Furthermore, we identify CTCF enrichment at cPRC1.2 loop anchors and at Polycomb group (PcG) bodies, suggesting that PRC1 and CTCF cooperatively regulate chromatin loops. Through virtual 4C and other genomic analyses, we discover that establishing neuronal progenitor cell (NPC) identity involves a switch from cPRC1.2-mediated chromatin loops to CTCF-mediated active loops. Our results suggest a novel mechanism by which pre-formed PRC1 loops at lineage-specific genes maintain a poised state for subsequent CTCF-mediated active loops and gene activation in cell fate transitions.
- Open Access
- 14 July 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4468-4482
PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells
Acute myeloid leukemia (AML) is an aggressive hematological malignancy that is sustained by leukemia-initiating cells (LICs). Although protein tyrosine phosphatase 4A2 (PTP4A2), also known as phosphatase of regenerating liver 2 (PRL2), is highly expressed in AML, the mechanisms by which PTP4A2 promotes leukemogenesis are largely unexplored. In this study, we demonstrate that PTP4A2 promotes AML by inhibiting the p53 tumor suppressor pathway in LICs. Using KMT2A-MLLT3–driven AML as a model, we found that PTP4A2 deficiency activates p53 and induces LIC apoptosis and senescence, thereby extending the survival of recipient mice repopulated with Ptp4a2−/− LICs. Mechanistically, PTP4A2 directly interacts with p53 and dephosphorylates it at serine 392, decreasing p53 stability and activity to enhance LIC proliferation and survival. Collectively, our findings identify p53 as a potential PTP4A2 substrate in leukemia cells and uncover a novel mechanism by which PTP4A2 enhances LIC maintenance.
- 14 July 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (13) , 4468-4482
Open AccessPTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells
Acute myeloid leukemia (AML) is an aggressive hematological malignancy that is sustained by leukemia-initiating cells (LICs). Although protein tyrosine phosphatase 4A2 (PTP4A2), also known as phosphatase of regenerating liver 2 (PRL2), is highly expressed in AML, the mechanisms by which PTP4A2 promotes leukemogenesis are largely unexplored. In this study, we demonstrate that PTP4A2 promotes AML by inhibiting the p53 tumor suppressor pathway in LICs. Using KMT2A-MLLT3–driven AML as a model, we found that PTP4A2 deficiency activates p53 and induces LIC apoptosis and senescence, thereby extending the survival of recipient mice repopulated with Ptp4a2−/− LICs. Mechanistically, PTP4A2 directly interacts with p53 and dephosphorylates it at serine 392, decreasing p53 stability and activity to enhance LIC proliferation and survival. Collectively, our findings identify p53 as a potential PTP4A2 substrate in leukemia cells and uncover a novel mechanism by which PTP4A2 enhances LIC maintenance.
- Open Access
- 2 July 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (7) , 1620-1631
Spatial transcriptomic analyses highlight distinct erythroid niches in mice and humans
Erythroid cells require specialized microenvironments called erythroblastic islands (EBIs), niches comprising a central macrophage surrounded by developing erythroid precursors, to complete their maturation. Understanding EBI composition and function has been limited by two-dimensional in vitro models and the unclear composition of EBIs in human hematopoietic tissues. Using spatial transcriptomic mapping in mouse and human hematopoietic tissues during development and under stress conditions, we show that EBI architecture is unexpectedly species-specific. In mice, C1q-expressing macrophages serve as a hallmark of EBI central macrophages and mediate clearance of ejected erythroid nuclei. In humans, however, EBIs are characterized by macrophage-independent erythroid clusters in fetal liver and bone marrow, whose integrity depends critically on the adhesion molecule ICAM4. These human erythroid clusters are disrupted in myeloid diseases but can be restored with therapy. These findings redefine conventional models of erythroid niche biology and establish a framework for understanding niche dynamics across species.
- 2 July 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (7) , 1620-1631
Open AccessSpatial transcriptomic analyses highlight distinct erythroid niches in mice and humans
Erythroid cells require specialized microenvironments called erythroblastic islands (EBIs), niches comprising a central macrophage surrounded by developing erythroid precursors, to complete their maturation. Understanding EBI composition and function has been limited by two-dimensional in vitro models and the unclear composition of EBIs in human hematopoietic tissues. Using spatial transcriptomic mapping in mouse and human hematopoietic tissues during development and under stress conditions, we show that EBI architecture is unexpectedly species-specific. In mice, C1q-expressing macrophages serve as a hallmark of EBI central macrophages and mediate clearance of ejected erythroid nuclei. In humans, however, EBIs are characterized by macrophage-independent erythroid clusters in fetal liver and bone marrow, whose integrity depends critically on the adhesion molecule ICAM4. These human erythroid clusters are disrupted in myeloid diseases but can be restored with therapy. These findings redefine conventional models of erythroid niche biology and establish a framework for understanding niche dynamics across species.
- 27 September 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 22 (1) , 94-103
PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL Phosphorylation
Receptor tyrosine kinase KIT is frequently activated in acute myeloid leukemia (AML). While high PRL2 (PTP4A2) expression is correlated with activation of SCF/KIT signaling in AML, the underlying mechanisms are not fully understood. We discovered that inhibition of PRL2 significantly reduces the burden of oncogenic KIT-driven leukemia and extends leukemic mice survival. PRL2 enhances oncogenic KIT signaling in leukemia cells, promoting their proliferation and survival. We found that PRL2 dephosphorylates CBL at tyrosine 371 and inhibits its activity toward KIT, leading to decreased KIT ubiquitination and enhanced AKT and ERK signaling in leukemia cells. Implications: Our studies uncover a novel mechanism that fine-tunes oncogenic KIT signaling in leukemia cells and will likely identify PRL2 as a novel therapeutic target in AML with KIT mutations.
- 27 September 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 22 (1) , 94-103
PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL Phosphorylation
Receptor tyrosine kinase KIT is frequently activated in acute myeloid leukemia (AML). While high PRL2 (PTP4A2) expression is correlated with activation of SCF/KIT signaling in AML, the underlying mechanisms are not fully understood. We discovered that inhibition of PRL2 significantly reduces the burden of oncogenic KIT-driven leukemia and extends leukemic mice survival. PRL2 enhances oncogenic KIT signaling in leukemia cells, promoting their proliferation and survival. We found that PRL2 dephosphorylates CBL at tyrosine 371 and inhibits its activity toward KIT, leading to decreased KIT ubiquitination and enhanced AKT and ERK signaling in leukemia cells. Implications: Our studies uncover a novel mechanism that fine-tunes oncogenic KIT signaling in leukemia cells and will likely identify PRL2 as a novel therapeutic target in AML with KIT mutations.
- Open Access
- 19 January 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (3) , 244-259
PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371
Acute myeloid leukemia (AML) is an aggressive blood cancer with poor prognosis. FMS-like tyrosine kinase receptor-3 (FLT3) is one of the major oncogenic receptor tyrosine kinases aberrantly activated in AML. Although protein tyrosine phosphatase PRL2 is highly expressed in some subtypes of AML compared with normal human hematopoietic stem and progenitor cells, the mechanisms by which PRL2 promotes leukemogenesis are largely unknown. We discovered that genetic and pharmacological inhibition of PRL2 significantly reduce the burden of FLT3-internal tandem duplications–driven leukemia and extend the survival of leukemic mice. Furthermore, we found that PRL2 enhances oncogenic FLT3 signaling in leukemia cells, promoting their proliferation and survival. Mechanistically, PRL2 dephosphorylates the E3 ubiquitin ligase CBL at tyrosine 371 and attenuates CBL-mediated ubiquitination and degradation of FLT3, leading to enhanced FLT3 signaling in leukemia cells. Thus, our study reveals that PRL2 enhances oncogenic FLT3 signaling in leukemia cells through dephosphorylation of CBL and will likely establish PRL2 as a novel druggable target for AML.
- 19 January 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (3) , 244-259
Open AccessPRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371
Acute myeloid leukemia (AML) is an aggressive blood cancer with poor prognosis. FMS-like tyrosine kinase receptor-3 (FLT3) is one of the major oncogenic receptor tyrosine kinases aberrantly activated in AML. Although protein tyrosine phosphatase PRL2 is highly expressed in some subtypes of AML compared with normal human hematopoietic stem and progenitor cells, the mechanisms by which PRL2 promotes leukemogenesis are largely unknown. We discovered that genetic and pharmacological inhibition of PRL2 significantly reduce the burden of FLT3-internal tandem duplications–driven leukemia and extend the survival of leukemic mice. Furthermore, we found that PRL2 enhances oncogenic FLT3 signaling in leukemia cells, promoting their proliferation and survival. Mechanistically, PRL2 dephosphorylates the E3 ubiquitin ligase CBL at tyrosine 371 and attenuates CBL-mediated ubiquitination and degradation of FLT3, leading to enhanced FLT3 signaling in leukemia cells. Thus, our study reveals that PRL2 enhances oncogenic FLT3 signaling in leukemia cells through dephosphorylation of CBL and will likely establish PRL2 as a novel druggable target for AML.
- 6 September 2012
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry
- Vol. 22 (43) , 23098-23105
In situ TPR removal: a generic method for fabricating tubular array devices with mechanical and structural soundness, and functional robustness on various substrates
Wire array templates have been utilized for fabricating various three-dimensional tubular structure devices, such as solar cells, batteries and supercapacitors, as well as electronic and photonic devices. It is necessary to remove the templates by using post-treatments such as wet chemical etching, decomposition, or Kirkendall approaches. However, it remains a challenge to ensure tubular structure integrity, mechanical soundness, and chemical purity during the template removal process, which affects the functional robustness of enabled tubular structure array devices. In this work, by utilizing ZnO nanorod array devices as templates and temperature programmed reduction (TPR) as the removal method, nanotube array devices made of various functional oxides have been directly converted with well-retained uniformity, structure and mechanical soundness, and chemical homogeneity on both two-dimensional (2D) planar and three-dimensional (3D) monolith device substrates. The successful examples range from binary metal oxides such as fluorite CeO2 to complex oxides like perovskite La0.8Sr0.2CoO3 (LSCO). This TPR removal method is generic, simple and rationally controllable, and can be easily expanded to the preparation of other oxides and non-oxide tubular structure devices regardless of the interfaced device substrate geometry. As a demonstration, the enabled CeO2 nanotube array devices could function as good high-temperature O2 sensors and active photocatalytic devices with good robustness.
- 6 September 2012
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry
- Vol. 22 (43) , 23098-23105
In situ TPR removal: a generic method for fabricating tubular array devices with mechanical and structural soundness, and functional robustness on various substrates
Wire array templates have been utilized for fabricating various three-dimensional tubular structure devices, such as solar cells, batteries and supercapacitors, as well as electronic and photonic devices. It is necessary to remove the templates by using post-treatments such as wet chemical etching, decomposition, or Kirkendall approaches. However, it remains a challenge to ensure tubular structure integrity, mechanical soundness, and chemical purity during the template removal process, which affects the functional robustness of enabled tubular structure array devices. In this work, by utilizing ZnO nanorod array devices as templates and temperature programmed reduction (TPR) as the removal method, nanotube array devices made of various functional oxides have been directly converted with well-retained uniformity, structure and mechanical soundness, and chemical homogeneity on both two-dimensional (2D) planar and three-dimensional (3D) monolith device substrates. The successful examples range from binary metal oxides such as fluorite CeO2 to complex oxides like perovskite La0.8Sr0.2CoO3 (LSCO). This TPR removal method is generic, simple and rationally controllable, and can be easily expanded to the preparation of other oxides and non-oxide tubular structure devices regardless of the interfaced device substrate geometry. As a demonstration, the enabled CeO2 nanotube array devices could function as good high-temperature O2 sensors and active photocatalytic devices with good robustness.